Log in
NYSE:GSK

GlaxoSmithKline SEC Filings & 10K Form

$36.18
-0.39 (-1.07 %)
(As of 10/19/2020 12:00 AM ET)
Add
Compare
Today's Range
$36.08
Now: $36.18
$36.77
50-Day Range
$35.98
MA: $38.12
$39.90
52-Week Range
$31.43
Now: $36.18
$48.25
Volume3.49 million shs
Average Volume3.76 million shs
Market Capitalization$90.76 billion
P/E Ratio10.74
Dividend Yield5.30%
Beta0.65

SEC Filings

GlaxoSmithKline (NYSE:GSK) SEC Filings

DateFilerForm TypeView
10/16/2020
6:43 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/14/2020
10:20 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/14/2020
10:11 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/13/2020
11:13 AM
GlaxoSmithKline (Subject)
NEW YORK STOCK EXCHANGE LLC (Filed by)
Form 25-NSE
10/13/2020
10:04 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/13/2020
9:17 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/13/2020
9:17 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/13/2020
8:39 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/13/2020
8:26 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/07/2020
9:33 AM
GlaxoSmithKline (Filer)
Form CERT
10/01/2020
1:52 PM
GLAXOSMITHKLINE CAPITAL PLC (Filer)
GlaxoSmithKline (Filer)
Form 8-A12B
10/01/2020
1:50 PM
GLAXOSMITHKLINE CAPITAL PLC (Filer)
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/01/2020
11:32 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/30/2020
9:56 AM
GLAXOSMITHKLINE CAPITAL PLC (Filer)
GlaxoSmithKline (Filer)
Form 424B2
09/28/2020
3:24 PM
GLAXOSMITHKLINE CAPITAL PLC (Filed by)
GlaxoSmithKline (Subject)
Form FWP
09/28/2020
3:22 PM
GLAXOSMITHKLINE CAPITAL PLC (Subject)
GlaxoSmithKline (Filed by)
Form FWP
09/28/2020
8:30 AM
GLAXOSMITHKLINE CAPITAL PLC (Filer)
GlaxoSmithKline (Filer)
GlaxoSmithKline (Filer)
Form 424B2
09/28/2020
7:53 AM
GLAXOSMITHKLINE CAPITAL PLC (Filer)
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/22/2020
12:46 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/18/2020
11:04 AM
BICYCLE THERAPEUTICS plc (Issuer)
GlaxoSmithKline (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/11/2020
11:49 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/10/2020
5:17 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/09/2020
9:57 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/09/2020
7:21 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/03/2020
5:21 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/01/2020
10:08 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/24/2020
3:12 PM
CureVac N.V. (Subject)
GlaxoSmithKline (Filed by)
Form SC 13G
08/13/2020
6:03 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/06/2020
5:21 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/03/2020
6:05 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/30/2020
7:56 PM
GENOCEA BIOSCIENCES, INC. (Issuer)
GlaxoSmithKline (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/29/2020
11:01 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/29/2020
9:34 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/29/2020
6:09 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/28/2020
10:19 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/24/2020
8:06 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/22/2020
4:23 PM
GlaxoSmithKline (Filed by)
Nkarta, Inc. (Subject)
Form SC 13D
07/22/2020
3:18 PM
GlaxoSmithKline (Reporting)
Pandion Therapeutics, Inc. (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/20/2020
6:36 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/16/2020
8:52 PM
GlaxoSmithKline (Reporting)
Pandion Therapeutics, Inc. (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
07/16/2020
7:13 PM
GlaxoSmithKline (Reporting)
Nkarta, Inc. (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/15/2020
6:20 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/15/2020
5:30 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/14/2020
3:48 PM
GlaxoSmithKline (Reporting)
Nkarta, Inc. (Issuer)
Form 3/A
07/14/2020
12:59 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/13/2020
12:27 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/10/2020
4:26 PM
CRISPR Therapeutics AG (Subject)
GlaxoSmithKline (Filed by)
Form SC 13D/A
07/10/2020
12:05 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/10/2020
11:25 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/10/2020
11:17 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/09/2020
7:58 PM
GlaxoSmithKline (Reporting)
Nkarta, Inc. (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
07/01/2020
7:46 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/29/2020
5:50 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/22/2020
4:29 PM
GlaxoSmithKline (Reporting)
Theravance Biopharma, Inc. (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/22/2020
4:13 PM
GlaxoSmithKline (Filed by)
Theravance Biopharma, Inc. (Subject)
Form SC 13D/A
06/19/2020
9:55 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/18/2020
11:41 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/18/2020
7:46 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/16/2020
7:43 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/11/2020
11:29 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/09/2020
8:56 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/04/2020
4:03 PM
GlaxoSmithKline (Filed by)
Spero Therapeutics, Inc. (Subject)
Form SC 13D/A
06/01/2020
11:23 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/26/2020
4:06 PM
GlaxoSmithKline (Filed by)
Turning Point Therapeutics, Inc. (Subject)
Form SC 13D/A
05/26/2020
3:17 PM
GlaxoSmithKline (Reporting)
Turning Point Therapeutics, Inc. (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/26/2020
6:32 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/21/2020
4:21 PM
GlaxoSmithKline (Reporting)
Progyny, Inc. (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2020
12:38 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/18/2020
5:50 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/13/2020
12:28 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/12/2020
5:23 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/11/2020
12:51 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/07/2020
10:31 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/06/2020
12:05 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/04/2020
12:01 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/04/2020
11:13 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/01/2020
12:42 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/30/2020
7:14 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/29/2020
7:21 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/16/2020
11:20 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/16/2020
9:36 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/16/2020
9:28 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/14/2020
12:46 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/14/2020
7:35 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/09/2020
7:50 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/06/2020
7:55 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/01/2020
8:43 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/01/2020
7:05 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/24/2020
5:27 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/20/2020
9:34 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/18/2020
8:23 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/11/2020
1:02 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/09/2020
11:49 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/09/2020
6:30 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/04/2020
10:17 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/02/2020
6:16 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/28/2020
3:48 PM
GENOCEA BIOSCIENCES, INC. (Subject)
GlaxoSmithKline (Filed by)
Form SC 13G/A
02/21/2020
7:23 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/20/2020
10:16 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/20/2020
8:44 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
This page was last updated on 10/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.